Previously a Director, David joined the partnership in April 2019.
David has extensive experience in antibody and vaccine technology, as well as gene editing technology involving antisense RNA and CRISPR. Prior to joining Greaves Brewster, David was in-house counsel and head of oppositions with Novartis AG, and thus has a good working knowledge of German.
David originally studied virology, which gave him a broad background in immunology and microbiology, including medical microbiology. During his studies, David spent a year carrying out molecular biology research at Novartis in Vienna.
As well as UK, European and Worldwide patent prosecution, David advises on SPCs, paediatric extensions, regulatory exclusivity, oppositions & appeals as well as litigation matters. Having managed the portfolios of blockbuster antibodies, David has been involved in due diligences, multi-million dollar licensing negotiations, high profile European opposition matters, litigation before the UK High Court and regulatory matters before the CJEU.
Year Joined Firm: 2014
Education/Alumni: University of Warwick
Network Memberships: OBN
